Drugs / Gadolinium-Chelate
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07705919 Background | Sep 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Ohio State University Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00602316 Background | Nov 2007 → Sep 2009 | female breast carcinoma | Royal Marsden NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gadolinium-Chelate | “Patients receive an injection of gadolinium chelate and undergo multifunctional magnetic resonance (MR) imaging” NCT00602316 ↗ |
| Route | Intravenous | “receive gadolinium based contrast intravenously (IV)” NCT07705919 ↗ |